Abstract
Cardiovascular disease remains the leading cause of death globally, with myocardial infarction (MI) and stroke representing critical emergencies that demand immediate and effective treatment. Traditional therapies, while lifesaving, often fall short in preventing the subsequent oxidative damage that occurs when blood flow is restored to the heart. This gap in care highlights an urgent need for innovative treatments that can mitigate the damaging effects of ischemia and reperfusion injury, thereby enhancing patient outcomes and survival rates.
Researchers at Florida Atlantic University have developed a novel class of drugs termed "resveramorphs". These bridged bicyclic compounds represent a significant step forward in preventing cardiovascular ischemia and reperfusion. By targeting the intricate mechanisms of ischemic and reperfusion injury, resveramorphs have shown promising neuro and cardioprotective effects in a preclinical model, suggesting their potential as therapeutic agents to prevent a heart attack.
FAU seeks to advance this innovation into the marketplace through licensing or development partnerships.
Benefit
Potential Novel Therapy - Demonstrates potent neuro and cardio protection in a preclinical modelInnovative Solution - Marks a significant breakthrough in preventing ischemic/reperfusion damageMarket Application
Emergency Cardiac Care - Potential therapeutic agent for high risk cardiac patientsCardiovascular Healthcare - Ideal for comprehensive cardiovascular treatment strategies
Brochure
